Cost-effectiveness analysis of Chaiyin Granules in treatment of influenza / 中国中药杂志

This study aimed to evaluate the cost-effectiveness of Chaiyin Granules compared with Oseltamivir Phosphate Capsules in the treatment of influenza(exogenous wind-heat syndrome). Based on a randomized, double-blind, positive drug parallel control clinical trial, this study evaluated the pharmacoeconomics of Chaiyin Granules with cost-effectiveness analysis method. A total of 116 patients with influenza from eight hospitals(grade Ⅱ level A above) in 6 cities were selected in this study, including 78 cases in the experimental group with Chaiyin Granules and Oseltamivir Phosphate Capsules placebo, and 38 cases in the control group with Oseltamivir Phosphate Capsules and Chaiyin Granules placebo. The total cost of this study included direct medical cost, direct non-medical cost, and indirect cost. The remission time of clinical symptoms, cure time/cure rate, antipyretic onset time/complete antipyretic time, viral nucleic acid negative rate, and traditional Chinese medicine(TCM) syndrome curative effect were selected as the effect indicators for cost-effectiveness analysis. Four-quadrant diagram was used to estimate the incremental cost-effectiveness ratio. The results showed that Chaiyin Granules were not inferior to Oseltamivir Phosphate Capsules in the remission time of clinical symptoms of influenza(3.1 d vs 2.9 d, P=0.360, non-inferiority margin was 0.5 d). Compared with Oseltamivir Phosphate Capsules, Chaiyin Granules would delay the remission time of clinic symptoms of influenza for 1 d, but could save 213.9 yuan. 1 d delay in cure time could save 149.3 yuan; 1% reduction in the cure rate could save 8.2 yuan; 1 d delay in antipyretic onset time could save 295.4 yuan; 1 d delay in complete antipyretic time could save 114.3 yuan; 1% reduction in the 5-day cure rate of TCM syndrome could save 19.2 yuan. Different from other indicators, there was no statistically significant difference between two groups in the effect of negative conversion rate of viral nucleic acid, but the cost was lower and the effect was superior, and the pharmacoeconomics was not different from that of Oseltamivir Phosphate Capsules in the field of influenza treatment.

Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia / 国际口腔科学杂志·英文版

Elevated fibroblast growth factor 23 (FGF23) in X-linked hypophosphatemia (XLH) results in rickets and phosphate wasting, manifesting by severe bone and dental abnormalities. Burosumab, a FGF23-neutralizing antibody, an alternative to conventional treatment (phosphorus and active vitamin D analogs), showed significant improvement in the long bone phenotype. Here, we examined whether FGF23 antibody (FGF23-mAb) also improved the dentoalveolar features associated with XLH. Four-week-old male Hyp mice were injected weekly with 4 or 16 mg·kg-1 of FGF23-mAb for 2 months and compared to wild-type (WT) and vehicle (PBS) treated Hyp mice (n = 3-7 mice). Micro-CT analyses showed that both doses of FGF23-mAb restored dentin/cementum volume and corrected the enlarged pulp volume in Hyp mice, the higher concentration resulting in a rescue similar to WT levels. FGF23-mAb treatment also improved alveolar bone volume fraction and mineral density compared to vehicle-treated ones. Histology revealed improved mineralization of the dentoalveolar tissues, with a decreased amount of osteoid, predentin and cementoid. Better periodontal ligament attachment was also observed, evidenced by restoration of the acellular cementum. These preclinical data were consistent with the retrospective analysis of two patients with XLH showing that burosumab treatment improved oral features. Taken together, our data show that the dentoalveolar tissues are greatly improved by FGF23-mAb treatment, heralding its benefit in clinics for dental abnormalities.

Evaluación de fugas extrarticulares del Fosfato crómico marcado con Fósforo-32 de producción nacional en pacientes hemofílicos / Evaluation of joint leakage of national Chromic Phosphate labeled with Phosphorus-32 in hemophilic patients

La radiosinoviortesis como tratamiento de la artropatía hemofílica, frecuentemente, ofrece excelentes resultados, al reducir grandemente el número de episodios de sangramiento y evitar daños ulteriores a las articulaciones. El Centro de Isótopos desarrolló el fosfato crómico coloidal marcado con Fósforo-32, producto listo para su empleo en pacientes hemofílicos. El objetivo de este trabajo fue evaluar la fuga extrarticular de este radiofármaco utilizado en la radiosinoviortesis en pacientes hemofílicos. Se determinó el porcentaje de fuga extrarticular del radiofármaco en 9 pacientes hemofílicos con sinovitis crónica, a los que se les realizó la radiosinoviortesis en la articulación de la rodilla. La radiactividad se midió, con un contador Geiger-Muller, sobre la rodilla tratada, en sus aspectos lateral, encima y medial; la rodilla contralateral; las cadenas linfáticas inguinales, de ambos lados, y el hígado. Los valores de fuga encontrados posteriormente a la inyección fueron 0,0046 por ciento a los 10 min; 0,0023 por ciento a las 24 horas; 0,1332 por ciento el día 7 y 4,0213 por ciento el día 30. Estos resultados coinciden con los valores comunicados por otros autores y con lo esperado de acuerdo a las características del producto, indican que se ejecutó el proceder adecuadamente y que los pacientes fueron seleccionados correctamente(AU)

Radiosynoviorthesis as a treatment for hemophilic arthropathy often offers excellent results, greatly reducing the number of bleeding episodes and avoiding further damage to the joints. The Isotope Center developed a product, Colloidal Chromic Phosphate labeled with Phosphorus-32, ready for use in hemophiliac patients. Our objective was to evaluate the joint leakage of this radiopharmaceutical use in radiosynoviorthesis in hemophilic patients. The percentage of radiopharmaceutical joint leakage was evaluated in 9 hemophilic patients with chronic synovitis, who underwent radiosynoviorthesis in the knee joint. The radioactivity was measured on the treated knee, in its lateral, above and medial aspects, the contralateral knee, the inguinal lymphatic chains of both sides and the liver, with a Geiger-Muller detector. The leakage values 8203;​found after the injection were 0.0046 percent at 10 minutes, 0.0023 percent at 24 hours, 0.1332 percent on day 7 and 4.0213 percent on day 30. These results are agreed with the values reported by other authors and with was expected according to the characteristics of the product, indicatate that the procedure was executed properly and that the patients were correctly selected(AU)

Tetania severa por uso de enemas fosfatados, reporte de caso / Tetany secondary to phosphate enema toxicity, case report

Los enemas fosfatados son utilizados frecuentemente en el tratamiento de la constipación. Errores en la posología pueden producir complicaciones graves. Objetivo: Reportar un caso de toxicidad grave por enema fosfatado en un pre escolar sin factores de riesgo. Caso clínico: Paciente de 2 años con constipación funcional, evaluada en servicio de urgencia por dolor abdominal a quién se le diagnosticó un fecaloma impactado. Recibió 2 dosis de enema de fosfato, “medio frasco” de Fleet® adulto (Synthon, Chile) por vez, sin resolución de su fecaloma, decidiéndose hospitalización para proctoclisis. Posterior al ingreso presentó un cuadro clínico de tetania. Ingresó a la Unidad de Paciente Crítico donde se confirmó una hiperfosfemia e hipocalcemia secundaria. Se realizó corrección electrolítica progresiva, retiro de enema fosfatado residual del recto e hiperhidratación forzando diuresis. La tetania cedió 2 horas después del ingreso sin otras complicaciones. Se realizó proctoclisis y fue dada de alta a los 3 días. Conclusión: Los enemas fosfatados pueden presentar complicaciones graves en niños sin factores de riesgo. Errores en la posología son la causa más frecuente de toxicidad en este grupo, pero esta puede estar favorecida también por una administración y eliminación inadecuadas. Pediatras y personal de salud que atiende a niños deben conocer factores de riesgo, signos y síntomas de intoxicación por enemas fosfatados.

Phosphate enemas are frequently used in the treatment of constipation. Errors in dosage and administration can lead to severe complications. Objective: To report a case of severe toxicity of phosphate enemas in a child with no risk factors. Case: 2 years old female, with functional constipation, was brought to emergency department because abdominal pain. She was diagnosed with fecal impaction and received half a bottle of Fleet Adult® (Laboratorio Synthon, Chile) two times, with no clinical resolution, deciding to start proctoclisis in pediatric ward. Soon after admission, she presented painful tetany, but alert and oriented. Patient was transferred to PICU where severe hyperphosphatemia and secondary hypocalcemia were confirmed. Her treatment included electrolyte correction; removal of residual phosphate enema and hyperhydration. Tetany resolved over 2 hours after admission and no other complications. Proctoclisis was performed and patient was discharged three days after admission with pharmacological management of constipation. Conclusion: Phosphate enemas may cause serious complications in children with no risk factors. Errors in dosage, administration and removal of the enema are causes of toxicity in this group. Pediatricians and health personnel must be aware of risks and signs of toxicity of phosphate enema.

Randomized Controlled Trial of Sodium Phosphate Tablets versus 2 L Polyethylene Glycol Solution for Bowel Cleansing prior to Colonoscopy / 대한소화기학회지

BACKGROUND/AIMS: Performance of polyethylene glycol solution (PEG) is often unsatisfactory as bowel preparation agent for colonoscopy. In order to provide equivalent efficacy with better patient tolerance, sodium phosphate tablet (SPT) has been developed. This study was carried out to compare the efficacy and compliance of two bowel preparation methods: PEG with ascorbic acid (PEGA) vs. SPT preparation. METHODS: A multicenter, randomized controlled trial was performed. Primary efficacy variable was overall quality of colon cleansing assessed by Boston bowel preparation scale (BBPS) during colonoscopy. Patient's satisfaction and adverse events were evaluated by means of symptom questionnaire completed by each patient immediately before colonoscopy. RESULTS: A total of 189 patients were randomly assigned to undergo pre-colonoscopic bowel preparation with either SPT (n=96) or PEGA (n=93). Overall BBPS score was 8.3+/-1.12 in the SPT group and 8.4+/-0.96 in the PEGA group (p=0.441). Among the 189 patients, 90 had polyps (47.6%) and 50 had adenomas (26.5%). The polyp/adenoma detection rate was 54.2% (n=52)/27.1% (n=26) for SPT group and 40.9% (n=38)/25.8% (n=24) for PEGA group (p=0.079 and 0.790, respectively). More number of patients were unable to take the prescribed dose of PEGA compared with the SPT regimen (8.6% vs. 2.0%, p=0.045). Overall satisfaction score was 7.9+/-1.63 in the SPT group and 7.4+/-1.53 in the PEGA group (p=0.022). CONCLUSIONS: Degree of colon preparation, polyp/adenoma detection rate and adverse effect were similar between SPT group and PEGA group. Patient compliance and satisfaction were greater in the SPT group.

The influence of desensitizing dentifrices on pain induced by in-office bleaching

The purpose of this study was to evaluate whether the use of desensitizing dentifrices used 15 days prior to and after in-office tooth bleaching could eliminate or reduce tooth sensitivity. After institutional review board approval and informed consent, 45 subjects were selected and divided into 3 groups according to the dentifrice selected: Colgate Total (CT), Colgate Sensitive Pro-Relief (CS) or Sensodyne ProNamel (SP). The subjects used toothpaste and a toothbrush provided to them for 15 days prior to bleaching. They were then submitted to two in-office bleaching sessions (Whiteness HP Blue Calcium). Their tooth sensitivity was assessed using the Visual Analog Scale (VAS) for a week after each session. Their tooth shade alteration was measured with a Vitapan Classical shade guide to determine if the dentifrices could influence the effectiveness of the bleaching agent. The data were submitted to Wilcoxon, Kruskal-Wallis and Mann-Whitney tests (α = 0.05). The use of desensitizing dentifrices did not affect the bleaching efficacy. In regard to tooth sensitivity, there was a statistically significant difference between the results of the Control Group and Group T2 after the first session (p = 0.048). There was no statistically significant difference in the results for the other groups after the first session. In regard to the second session, there was no statistically significant difference in the results for all the groups. The use of a desensitizing dentifrice containing nitrate potassium reduced tooth sensitivity during the bleaching regimen. Dentifrices containing arginine and calcium carbonate did not reduce tooth sensitivity. Color change was not influenced by the dentifrices used.

Riesgos de la preparación colónica con fosfato sódico / Risks of sodium phosphate colonic cleansing

Introducción. La difusión de la colonoscopía incrementó el uso del fosfato sódico oral (NaP). Se han notificado complicaciones como deshidratación, hipotensión, insuficiencia renal aguda e insuficiencia renal crónica con nefrocalcinosis, y hasta casos fatales de hiperfosfatemia severa. Basado en la evidencia científica actual, en el presente trabajo se presentan los riesgos y contraindicaciones de la utilización de laxantes de fosfato sódico y cómo evitarlos. Material y métodos. Se realizó un análisis bibliográfico sobre el tema en PubMed y Google Advanced Search, de publicaciones en español e inglés, en el que se incluyen ensayos clínicos, revisiones bibliográficas, cartas, editoriales, guías prácticas, meta análisis y revisiones Cochrane. Resultados. Las complicaciones por NaP se relacionan con patologías que incrementan la absorción del fosfato, con hiperparatiroidismo y con disfunción renal. También se asocian con dosis mayores a 60 g y con intervalos entre las tomas menores a 5 h, y son facilitadas por la deshidratación. Se reportaron algunos casos en los que no se respetaron estas condiciones. La insuficiencia renal por nefrocalcinosis es irreversible. Conclusión. Se debe realizar una selección adecuada de los pacientes para evitar el uso de NaP en aquellos que presenten riesgo de desarrollar hiperfosfatemia o insuficiencia renal; además, es necesario efectuar una correcta hidratación oral, no administrar más de 60 g de NaP y evitar que los intervalos entre las dosis sean menores a 5 h.

Introduction. The spread of colonoscopy has increased the use of oral sodium phosphate (OSP). Complications such as dehydration, hypotension, acute renal failure and chronic kidney disease with nephrocalcinosis and even fatal cases of severe hyperphosphatemia have been reported. The risk and contraindications of OSP use and the ways to avoid them are shown in this paper according to the scientific evidence. Material and methods. Bibliographic analysis on this subject is carried in PubMed and Google Advanced Search, publications in Spanish and English, including clinical trials, bibliographic revisions, letters, editorials, practical guidelines, meta analyses and Cochrane reviews. Results. OSP complications are related to pathologies that increase its absorption, with hyperparathyroidism and with kidney impairment. They are also associated with OSP doses >60 g and with dose intervals <5 h and are facilitated by dehydration. Some cases have been reported in patients without those conditions. Nephrocalcinosis kidney disease is irreversible. Conclusion. Adequate patient selection is mandatory to avoid OSP in patients with risk of developing hyperphosphatemia or renal impairment; proper oral hydration is also essential as is not administering more than 60 g OSP, and avoiding dose intervals <5 h.

Introdução. A difusão da colonoscopia aumentou o uso de fosfato de sódio oral (NaP). Têm sido relatadas complicações como desidratação, hipotensão, insuficiência renal aguda e insuficiência renal crônica com nefrocalcinose, e até casos fatais de hiperfosfatemia severa. Com base na evidência científica atual, são apresentados os riscos e contraindicações da utilização de laxantes de fosfato de sódio e a forma de evitá-los. Material e métodos. Foi feita uma análise bibliográfica sobre o tema (publicações em espanhol e inglês) em PubMed e Google Advanced Search que abrange ensaios clínicos, revisões bibliográficas, cartas, editoriais, guias práticos, meta-análise e revisões Cochrane. Resultados. As complicações por NaP se associam a patologias que aumentam a absorção de fosfato, a hiperparatiroidismo e a disfunção renal. Também se associam a doses maiores que 60 g e intervalos entre as tomadas menores que 5 h, e são facilitadas pela desidratação. São relatados casos em estas condições não foram respeitadas. A insuficiência renal por nefrocalcinose é irreversível. Conclusão. Deve ser feita uma seleção adequada dos pacientes para evitar o uso de NaP naqueles com risco de desenvolver hiperfosfatemia ou insuficiência renal; além disso, é necessário realizar uma correta hidratação oral, não administrar mais do que 60 g de NaP e evitar intervalos entre as doses menores que 5 h.

The efficacy of a herbal-based toothpaste in the control of plaque and gingivitis: A clinico-biochemical study.

Objective: A double-blinded controlled clinical trial with parallel groups was designed to investigate the effectiveness of a herbal-based toothpaste in the control of plaque and gingivitis as compared with a conventional dentifrice. The efficacy of Colgate Herbal over Colgate tooth paste was assessed in this study. Materials and Methods: Thirty subjects with gingivitis participated in the study. All participants had at least 20 natural teeth with no probing depths greater than 3 mm and a plaque index score of 2 or more at baseline. At baseline, the clinical parameters like gingival index, plaque index and salivary pH were estimated. Paired t-test was used to compare the difference within the groups and unpaired t-test was used to compare the difference between the groups at baseline and on the 30 th day. Results: At the end of the study, there were statistically significant reductions in the gingival index and the plaque index scores within the test group. However, there were no statistically significant differences between the test and the control groups. The salivary pH changes were not statistically significant in the test group but were displaced more toward the acidic range in the control group. Conclusion: It was however concluded that the herbal-based toothpaste was as effective as the conventionally formulated dentifrice in the control of plaque and gingivitis.

Tripolifosfato de sódio e hexametafosfato de sódio na prevenção do cálculo dentário em cães / Sodium tripolyphosphate and sodium hexametaphosphate in preventing dental calculus accumulation in dogs

Avaliou-se o efeito de dois fosfatos, tripolifosfato de sódio (TPF) e hexametafosfato de sódio (HMF), incorporados à ração seca sob diferentes formas, como cobertura do grânulo da ração e no interior da massa da ração, na prevenção do desenvolvimento de cálculo dentário em 25 cães. O delineamento experimental utilizado foi inteiramente ao acaso, com cinco tratamentos e cinco repetições. Os tratamentos experimentais foram: 1) ração seca; 2) ração seca com TPF incorporado na cobertura do grânulo da ração; 3) ração seca com TPF incorporado na massa da ração; 4) ração seca com HMF incorporado na cobertura do grânulo da ração; 5) ração seca com HMF incorporado na massa da ração. Os animais receberam as dietas por um período experimental de 90 dias e, após esse período, foram submetidos à avaliação da área de cálculo dentário formado. A inclusão do HMF na ração seca, tanto na cobertura dos grânulos como no interior da massa, e do TPF, como cobertura dos grânulos, reduziu o acúmulo de cálculo dentário em cães, comparada à dieta sem adição de fosfatos. O HMF foi o fosfato mais eficiente, ao reduzir o acúmulo de cálculo dentário em até 47 por cento. As formas de inclusão do HMF na ração não influenciaram o acúmulo de cálculo dentário. Houve redução do desenvolvimento de cálculo dentário pela incorporação do TPF como cobertura do grânulo da ração, comparada à inclusão deste fosfato no interior da massa da ração. Conclui-se que os fosfatos incorporados na ração seca reduzem o acúmulo de cálculo dentário em cães.

The effect of dry food treated with sodium tripolyphosphate (TPP) or sodium hexametaphosphate (HMP), as kibble coated or added into the interior of the kibble on the accumulation of dental calculus in 25 dogs was evaluated. The study used a completely randomized design with five treatments and five repetitions. The experimental treatments were: 1) dry food; 2) dry food coated with TPP; 3) dry food with TPP incorporated into the interior of the kibble; 4) dry food coated with HMP; 5) dry food with HMP incorporated into the interior of the kibble. The animals received the diets for a 90-day experimental period, and then, the teeth were clinically examined for the presence of calculus. The inclusion of HMP in the dry food, as kibble coated or added into the interior of the kibble, and the inclusion of TPP as kibble coated reduced the accumulation of dental calculus compared to the control group without anti-calculus agents. HMP was the most efficient phosphate, reducing the accumulation of dental calculus in 47 percent. The forms of HMP inclusion in the dry food exerted no significant effect upon calculus formation. However, there was a reduction of calculus accumulation when TPF was incorporated as coating of the kibble, compared to the inclusion of this phosphate into the interior of the kibble. It was concluded that phosphates incorporated in the dry food reduce the accumulation of dental calculus in dogs.

Oral potassium chloride and oral rehydration solution supplement to prevent hypokalemia in sodium phosphate regimen for bowel preparation prior to gynecological laparoscopic surgery.

OBJECTIVE: To evaluate the efficacy of oral potassium chloride and oral rehydration solution (ORS) supplement for hypokalemia prevention after sodium phosphate (NaP) bowel preparation. MATERIAL AND METHOD: A comparative historical study of patients who underwent gynecological laparoscopic surgery between June 2005 and December 2007 and received NaP for bowel preparation prior to surgery. In the experiment group, a 10% Potassium chloride (KCl) elixir and ORS supplement was introduced to 47 of the patients. The control group of 42 patients received only pure water Age, body mass index, and time of defecation after NaP bowel preparation were recorded. Serum potassium level before NaP (K0), 4 hours (K4), and 10 hours (K10) after last dose of NaP were measured in both groups. RESULTS: It was found that the experiment group could maintain serum potassium level well. The mean +/- SD of serum potassium level before NaP (K0), at 4 hours after NaP (K4) and at 10 hours after NaP (K10) were 3.99 +/- 0.35, 4.09 +/- 0.43, 4.03 +/- 0.63, respectively. In the control group, the K0 was similar to that in the experiment group but the K4 decreased to 3.50 +/- 0.35 and K10 was 3.76 +/- 0.40 which had a significant difference (p = 0.011). Serum hypokalemia (K < 3.5 mmol/L) was found in 22 patients (52.38%) of the control group. CONCLUSION: Oral KCl elixir and ORS supplement for sodium phosphate bowel preparation regimen can prevent hypokalemia prior to surgery.

Osteomalacia tumoral / Tumoral osteomalacia

La osteomalacia tumoral (OT) u osteomalacia oncogénica es un síndrome paraneoplásico producido por una pérdida renal de fosfato. Es una enfermedad rara, con aproximadamente 130 casos publicados. Recientemente, se han descrito varios factores de origen óseo que participarían en el mantenimiento de la homeostasis del fósforo; en conjunto se los denomina ?fosfatoninas?, y el más conocido es el Factor de Crecimiento Fibroblástico 23 (FGF-23). Ésta es una hormona proteica detectable en el suero de sujetos sanos y ha sido relacionado con la fisiopatología de tres tipos de raquitismo/osteomalacia con hipofosfatemia: dos enfermedades hereditarias (raquitismo u osteomalacia hipofosfatémicos asociado/a al cromosoma X [XLH], y raquitismo u osteomalacia autosómicos dominantes [ADHR]), y la OT. Los tumores asociados a la OT son de origen mesenquimático, de crecimiento lento, complejos y polimórficos. En general estos tumores son benignos, de tamaño pequeño, asintomáticos y de localización incierta; también se ha descrito el cuadro en asociación con neoplasias malignas. El diagnóstico presuntivo requiere la documentación de hipofosfatemia y de una disminución marcada en la reabsorción tubular de fósforo. Deben registrarse los antecedentes familiares, y proceder a estudios de localización del tumor: la TC y la RNM son de poca utilidad, y recientemente se ha visto la sensibilidad de centellogramas con análogos de somatostatina y del PET scan con fluorodesoxiglucosa. El diagnóstico de certeza se obtiene si se logra la reversión de la hipofosfatemia con la extracción del tumor. El tratamiento médico requiere dosis altas de fosfatos y calcitriol por vía oral, no siempre bien tolerados. Se han usado también el octreotide y el calcimimético cinacalcet. El tratamiento curativo es la remoción quirúrgica del tumor causante.

Comparison of colon-cleansing methods in preparation for colonoscopy - Comparative efficacy of solutions of mannitol, sodium picosulfate and monobasic and dibasic sodium phosphates / Estudo comparativo entre as soluções de manitol, picossulfato de sódio e fosfato monobásico e dibásico de sódio no preparo de cólon para colonoscopia

PURPOSE: Colonoscopy plays an essential role in the therapeutic and diagnostic approach in various colonic pathologies, the aim of the present study was to compare three solutions and their efficacy for the bowel preparation in adult patients submitted to elective colonoscopy. METHODS: Sixty patients were randomly divided into three groups of 20 each. Each group was submitted to a bowel preparation with one of the following solutions: 10 percent manitol, sodium picosulphate or sodium phosphate. The parameters evaluated were: taste, tolerance, associated side effects and quality of cleansing. Postural blood pressure and pulse rate as well as serum sodium, potassium, calcium and phosphate were compared. RESULTS: Sodium phosphate and 10 percent manitol solutions provided superior results in terms of colon cleansing compared to sodium picosulphate solution. All serum electrolytes evaluated were significantly altered in the three groups, without important clinical signs. DISCUSSION: High levels of serum phosphate were the most striking alteration in patients prepared with sodium phosphate solution, again with no clinical signs. Variations related to blood pressure and pulse rate suggested contraction of intravascular volume, with no clinical effects. CONCLUSION: Sodium phosphate and 10 percent manitol solutions are equivalent in providing good quality colon cleansing, with no significant side effects that could compromise the procedure.

INTRODUÇÃO: A colonoscopia é exame fundamental na avaliação das doenças do cólon e na abordagem terapêutica de determinado grupo de patologias. O preparo intestinal é obrigatório para a realização das colonoscopias eletivas, e a qualidade encontra-se relacionada ao sucesso do procedimento. Comparou-se três soluções para limpeza anterógrada do cólon em pacientes adultos, submetidos à colonoscopia. METODOS: Sessenta pacientes foram distribuídos em três grupos de vinte. Cada grupo realizou o preparo do cólon com uma das três soluções estudadas: manitol a 10 por cento (MN), picossulfato sódico (PS) e fosfato monobásico e dibásico de sódio (NaP). O sabor, a tolerância, os efeitos colaterais, os custos e a qualidade de limpeza do preparo foram avaliados. Frequência cardíaca e pressão arterial sistêmica foram analisados. Variações dos eletrólitos foram dosados antes e após o preparo. RESULTADOS: Os resultados foram semelhantes em relação aos efeitos colaterais. O sabor da solução de NaP não chegou a comprometer a sua aceitação. DISCUSSÃO: Soluções de NaP e MN proporcionaram resultados superiores tanto em qualidade de limpeza colônica, como em relação aos custos, quando comparadas à solução de PS. CONCLUSÃO: Comparados os três, os eletrólitos avaliados apresentaram diferenças significativas, sendo a hiperfosfatemia dos pacientes com a solução de NaP, a mais importante.

Bone disease in preterm.

The survival rate of premature infants has significantly increased during the last few decades. As a consequence, new disorders such as osteopenia of prematurity have been emerging. We report 6 month evolution from diagnosis to recovery of a patient with metabolic bone disease of prematurity who showed a remarkable improvement on therapy with phosphate, calcium and vitamin D.

Hiperparatireoidismo associado à osteomalacia hipofosfatêmica do adulto: relato de caso e revisão da literatura / Hyperparathyroidism associated with hypophosphatemic osteomalacia: case report and review of the literature

A osteomalacia hipofosfatêmica é uma doença rara caracterizada por hipofosfatemia, níveis elevados de fosfatase alcalina e diminuição da densidade óssea. O tratamento é realizado com suplementação oral com fosfato e vitamina D e, nos casos de osteomalacia oncogênica, com a ressecção do tumor. Relatamos o caso de uma paciente que apresentou quadro de osteomalácia hipofosfatêmica de causa indeterminada. Apesar de extensivamente procurado, nenhum tumor produtor de substância hipofosfatêmica foi localizado. A paciente foi tratada como suplementação de fosfato e vitamina D por longo período, evoluindo com quadro de hiperparatireoidismo terciário. A retirada de três paratireóides não normalizou os níveis de PTH e a paciente recusou-se a continuar a investigação e o tratamento. Após dez anos de tratamento irregular, foi internada por insuficiência respiratória causada por colabamento do arcabouço costal e múltiplas fraturas, evoluindo para o óbito. Os autores discutem a relação entre osteomalácia e hiperparatireoidismo e o curso agressivo da doença.

Respuesta productiva y mineralización ósea de pollos de engorde alimentados con fosfatos sedimentarios según biodisponibilidad del fósforo / Growth and bone mineralization of broiler chicks fed with sedimentary phosphates adjusted by phosphorus bioavailability

En pollos de engorde se determinó el efecto de aporte de fósforo de fosfatos de yacimientos no defluorinados, ajustados a su biodisponibilidad específica, sobre la ganancia de peso y mineralización ósea. Los fosfatos fueron Riecito (RIO), Monte Fresco (MONTE) y Navay (NAVAY) con biodisponibilidad relativa al fosfato dicalcico (DICAL, 100%) de 81,0; 68,0 y 68,1%, respectivamente. A la sexta semana de edad los pesos (g) y el contenido de ceniza de la tibia (mg.cc) fueron de 2063,3 y 215,2; 1944,2 y 199,1; 1700,5 y 197,6, respectivamente, para el mismo orden de los fosfatos, siendo los valores de RIO similares a los de DICAL (2051,6 g; 217,2 mg.cc), y superiores (P<0,05) a los demás fosfatos. Los niveles de flúor (ppm) del hueso fueron de 1145, 6000, 8333 y 14925, para la DICAL, RIO, MONTE y NAVAY, respectivamente.

Distintas formas de presentación clínica de un raquitismo hipofosfatémico autosómico dominante por mutación del factor de crecimiento fibroblástico 23 en una familia / Different forms of clinical presentation of an autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation in one family

In this report we describe different forms of clinical presentation of an autosomal dominant hypophosphatemic rickets (ADHR) in 4 members of the same family as well as the treatment used in these patients and their response to it. Patient No 1: a 60 year old female who consulted for bone pain: Bone densitometry showed osteoporosis. Laboratory assays showed hypophosphatemia with low renal phosphate threshold, high total alkaline phosphatase, normal intact PTH and normal serum calcium. With neutral phosphate and calcitriol, the biochemical parameters normalized and bone densitometry improved significantly in less than a year. Patient No 2 her grand daughter consulted at 1 year and 8 months of age for growth retardation (height at percentile 3) and genu varum. Laboratory assays showed low serum phosphate and high total alkaline phosphatase; thickening and irregular epiphyseal borders of the wrists were observed radiologically. She began treatment with calcitriol and phosphorus with normalization of laboratory parameters and increase in growth (height increasing to percentile 50 after 20 months of therapy). Patient No 3: mother of patient No 2, she had no clinical manifestations and normal densitometry but presented low serum phosphate (1.9 mg/dl) that normalized with neutral phosphate therapy. Patient No 4: he was the youngest son of Patient No 1, who had had hypophosphatemic rickets, by age 5; his serum phosphate normalized without treatment At age 29, he presented normal serum phosphate and bone densitometry. Genomic DNA analysis performed in patient No 3, showed missense mutation with substitution of arginine at position 179 for glutamine. The family was catalogued as having autosomal dominant hypophosphatemic rickets/osteomalacia.

Describimos distintas formas de presentación clínica de un raquitismo hipofosfatémico autosómicodominante en 4 miembros de una misma familia y su respuesta al tratamiento. Paciente N° 1: de sexofemenino de 60 años que consultó por dolores costales y pélvicos, con osteoporosis densitométrica, hipofosfatemia con bajo umbral renal de fósforo, PTH intacta normal y calcemia normal. Tratada con fósforo neutro y calcitriol logró la normalización bioquímica y una notable mejoría de la densitometría en menos de un año. Paciente N° 2: su nieta, consultó al año y ocho meses de edad por presentar talla en percentil 3 y genu varum. En el laboratorio mostró hipofosfatemia y fosfatasa alcalina total muy elevada y en la Rx de mano, ensanchamiento y deflecamiento epifisario compatible con raquitismo. Tratada con fósforo neutro y calcitriol, normalizó los parámetros bioquímicos y logró un ascenso en el percentil de talla de 3 a 50 a los 20 meses de tratamiento. Paciente N° 3: la madre de la paciente N° 2, quien sin ninguna manifestación clínica y con densitometría ósea normal presentó hipofosfatemia que se normalizócon tratamiento con fosfato neutro. Paciente N° 4: el tío de la paciente N° 2, tuvo raquitismo hipofosfatémico de niño,y luego de los 5 años normalizó el fósforo sin tratamiento. Estudiado a los 29 años presentó fósforo normal y densitometría ósea normal. El análisis del ADN genómico de la paciente N° 3 mostró una mutación con sentido erróneo en el gen del factor de crecimiento fifroblástico 23 (sustitución de arginina por una glutamina en posición 179). Por lo tanto se llegó al diagnóstico de raquitismo/osteomalacia hipofosfatémico autosómico dominante.

In postmenopausal osteoporosis the bone increasing effect of monofluorophosphate is not dependent on serum fluoride

According to previous pharmacokinetic studies the biovailability of fluorine (F) from sodium monofluorophosphate (MFP) doubles that of sodium fluoride (NaF). This paper reports a study designed to verify whether the vertebral bone mass increasing effect of NaF (30 mg F/day) was comparable to that of MFP (15 mg F/day), given for 18 months to osteoporotic postmenopausal women. The BMD of lumbar vertebrae of both groups showed significant increases (MFP: 60 + 15 mg/cm2, NaF: and 71 + 12 mg/cm2) over basal levels (P < 0.001). The difference between treatments was not significant (P = 0.532). The serum levels of ionic F (the mitogenic species on osteoblasts) were not related to the above mentioned effects. In NaF-treated patients, the fasting levels of total serum F increased significantly (6.7 + 0.9 muM vs. Basal: 2.0 + 0.8 muM; P < 0.001). This phenomenon was accounted for by ionic fluoride that increased over 20-fold (6.5 + 1.9 muM vs. Basal: 0.3 + 0.04 muM). In MFP-treated patients the fasting serum levels of total (7.0 + 0.7 muM vs. Basal: 2.2 + 0.9 M) and diffusible F (0.5 + 0.02 muM vs. Basal 0.2 + 0.02 muM) increased significantly (P < 0.001). The increase in the non diffussible F fraction is accounted for by proteinboud F, probably by the complexes formed between MFP and alpha2-macroglobulin and C3. Serum diffusible F was formed by two fractions: ionic F and F bound to low molecular weight macromolecule/s (2 200 + 600 Da), in approximately equal amounts. The general information afforded by the present observations support the hypothesis that ionic F is released progressively during the metabolism of MFP bound to alpha2-macroglobulin and C3. These phenomena explain why comparable effects to those obtained with 30 mg F/d of NaF could by obtained with one half the dose of MFP.

Limpieza colónica mecánica, polietilenglicol vs. una nueva preparación de bajo volumen: evaluación prospectiva, randomizada y ciega / Colonic cleasing: polyethilenglicol vs. minimum volume solution: prospective, randomized and double blind study

Introducción y objetivo: el método para lograr una adecuada limpieza colónica debe ser eficaz, seguro, bien tolerado y de fácil implementación. Muchas variantes han sido probadas, siendo actualmente la solución de polietilenglicol (PEG) la más utilizada. Su principal desventaja es el volumen que debe ingerirse (4 litros). Esto motivó la introducción de una solución de bajo volumen (90 ml) a base de fosfatos sódicos (FS). El objetivo del presente trabajo fue el de comparar ambas soluciones en términos de eficacia, tolerancia y costos. Material y método: entre Setiembre de 1995 y Marzo de 1996, 373 pacientes que debían someterse a videocolonoscopia, colon por enema o cirugía colorrectal fueron randomizados para recibir solución de PEG (n = 188) o de FS (185). En el mismo período, a 42 pacientes que habían recibido previamente PEG y debían repetir la preparación se les indicó FS. La tolerancia fue evaluada a través de cuestionarios completados por los mismos pacientes y la eficacia por médicos endoscopistas, radiólogos o cirujanos que no conocían la solución administrada. Resultado: la proporción de limpieza aceptable (excelente o buena) fue similar en ambos grupos (PEG: 88,2 por ciento), FS: 82,2 por ciento, p > 0,05). Considerando los grados de tolerancia "excelente" y "buena" en conjunto, no hubo diferencias entre los grupos (PEG: 65 por ciento, FS 65,5 por ciento), p > 0,05). Tampoco la incidencia de efectos adversos fue significativamente diferente (PEG: 60 por ciento, FS 58 por ciento, p > 0,05). Sin embargo, una menor proporción de pacientes pudieron completar la ingesta de PEG (PEG: 71 por ciento, FS 88 por ciento, p < 0,01). Ademas, 41 de los 42 pacientes que habían recibido previamente PEG evaluaron al FS como "mejor" o "mucho mejor". No se registró ninguna complicación grave atribuible a las diferentes preparaciones. La diferencia en el costo total durante el período de estudio fue de 5858,33 pesos a favor del FS. Conclusiones: la presente es la primera evaluación comparativa prospectiva, randomozada y ciega entre las soluciones de PEG y FS para la preparación colónica en estudios endoscopicos, radiológicos y quirúrgicos. La nueva preparación se mostró tan efectiva y segura como la de PEG. Si bien la tolerancia y el desarrollo de efectos adversos fueron similares en ambos grupos, los pacientes que habían tomado PEG previamente mostraron una marcada preferencia por el nuevo preparado. La reducción del costo es una ventaja adicional para la...